Jagsonpal to acquire Group Pharmaceuticals’ wellness portfolio for up to ₹46.7 crore
Jagsonpal Pharmaceuticals will buy Group Pharmaceuticals’ India wellness portfolio via a slump sale, adding women’s healthcare and adjacent therapies to its national commercial platform. The deal includes ₹23.7 crore at closing and up to ₹23 crore tied to FY2027-28 sales.
What happened
Jagsonpal Pharmaceuticals will acquire Group Pharmaceuticals’ India wellness portfolio through a slump sale for up to ₹46.7 crore, expanding women’s healthcare
Key facts
- Up to ₹46.7 crore total consideration
- ₹23.7 crore initial consideration at closing
- Up to ₹23 crore earn-out linked to FY2027-28 sales
- ₹24.6 crore wellness portfolio turnover in FY2025-26
- Completion expected on or before November 1, 2026
What changed
Jagsonpal Pharmaceuticals will acquire Group Pharmaceuticals’ India wellness portfolio through a slump sale for up to ₹46.7 crore, expanding women’s healthcare and complementary therapeutic offerings through its pan-India distribution network and commercial platform.
Why this matters
Jagsonpal must integrate Group Pharmaceuticals’ wellness brands into its national salesforce while protecting continuity in women’s healthcare channels ahead of the targeted November 2026 close.
What to watch
- Completion timing versus the November 1, 2026 target and any conditions, approvals or transition-service arrangements disclosed.
- Final asset list, brand ownership, manufacturing agreements and whether key trademarks and product registrations transfer cleanly.
- Post-close commentary on revenue contribution, gross margin, sales-force overlap and integration costs.
- FY2027-28 portfolio sales performance relative to the ₹23 crore contingent-payment threshold.
- Distributor retention, prescription momentum and availability of flagship women’s-health products after transfer.